Arcturus Therapeutics Holdings INC Form 4 insider transactions

Arcturus Therapeutics Holdings Inc. director Edward W. Holmes acquired 15,000 stock options with an exercise price of $7.30, vesting over one year.

Arcturus Therapeutics Holdings Inc. director Peter C. Farrell was granted stock options for 15,000 shares.

Arcturus Therapeutics Holdings Inc. director James F. Barlow acquired 15,000 stock options with an exercise price of $7.30, vesting monthly over one year.

Arcturus Therapeutics Holdings Inc. director John Markels acquired stock options as part of his annual grant, with vesting over one year.

Arcturus Therapeutics Holdings Inc. director Moncef Slaoui was granted stock options for 15,000 shares.

Arcturus Therapeutics Holdings Inc. reports that Director Magda Marquet acquired 15,000 stock options.

Arcturus Therapeutics Holdings Inc. Director Jing L. Marantz acquired 15,000 stock options as part of an annual grant.

Arcturus Therapeutics Holdings Inc. reports that Chief Financial Officer Dennis Mulroy acquired 100,000 employee stock options.

Arcturus Therapeutics Holdings Inc. Controller Joseph Roberts received a grant of 10,000 employee stock options with an exercise price of $6.52.

Arcturus Therapeutics Holdings Inc. granted its Chief Scientific Officer & COO, Pad Chivukula, 54,000 employee stock options with an exercise price of $6.52.

Arcturus Therapeutics Holdings Inc. CEO Joseph E. Payne was granted 175,000 employee stock options with an exercise price of $6.52, vesting over four years.

Arcturus Therapeutics Holdings Inc. granted 54,000 employee stock options to Chief Legal Officer Lance Kurata with an exercise price of $6.52.

Arcturus Therapeutics CFO Andy Sassine acquired 1,238 shares of common stock through the company's Employee Stock Purchase Plan.

Arcturus Therapeutics Holdings Inc.'s CFO, Andy Sassine, acquired 1,238 shares of common stock through the company's Employee Stock Purchase Plan.

Arcturus Therapeutics Holdings Inc. Director Peter C. Farrell was granted 15,000 stock options with an exercise price of $12.54 as part of his 2025 annual compensation.

Arcturus Therapeutics Holdings Inc. director Moncef Slaoui was granted 15,000 stock options with an exercise price of $12.54 as part of his 2025 annual board compensation.

Magda Marquet, a Director at Arcturus Therapeutics Holdings Inc., was granted 15,000 stock options with an exercise price of $12.54 as part of her 2025 annual compensation.

Arcturus Therapeutics Holdings Inc. director John Markels was granted 15,000 stock options with an exercise price of $12.54 as part of his 2025 annual compensation.

Arcturus Therapeutics Holdings Inc. director Jing L. Marantz was granted 15,000 stock options with an exercise price of $12.54 as part of her 2025 annual board compensation.

Arcturus Therapeutics Holdings Inc. director James F. Barlow was granted 15,000 stock options with an exercise price of $12.54 as part of his 2025 annual compensation.

Arcturus Therapeutics Holdings Inc. director Edward W. Holmes was granted 15,000 stock options with an exercise price of $12.54 as part of his 2025 annual board compensation.

Lance Kurata, Chief Legal Officer of Arcturus Therapeutics, was granted stock options to purchase 60,000 shares of common stock on December 16, 2024.

Arcturus Therapeutics CEO, Joseph E. Payne, was granted 196,000 stock options on December 16, 2024, according to a recent SEC filing.

Arcturus Therapeutics' Chief Scientific Officer and COO, Pad Chivukula, was granted 60,000 stock options on December 16, 2024.

Arcturus Therapeutics' Chief Financial Officer, Andy Sassine, was granted 60,000 stock options on December 16, 2024, according to a recent SEC filing.

Arcturus Therapeutics' Chief Scientific Officer & COO, Pad Chivukula, sold 12,000 shares of common stock at an average price of $20.7601 on October 15, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Director Moncef Slaoui acquired stock options in Arcturus Therapeutics Holdings Inc. on June 19, 2024.

Director Jing L. Marantz reports acquisition of stock options and disposal of deferred stock units in Arcturus Therapeutics.

Director Edward W. Holmes reports acquisition of stock options and deferred stock units conversion to common stock in Arcturus Therapeutics Holdings Inc.

Director John Markels reports acquisition of stock options and vesting of deferred stock units in Arcturus Therapeutics.